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Introduction
An astonishing volume of
material has been published about
Alzheimer’s disease in recent years.
Typing the word “Alzheimer’s”
into Google will reward you with
13,600,000 “results” in 0.15 seconds,
and a PubMed search of the same
instantly yields over 55,000 journal
articles. Yet, primary care physicians
(PCPs) who regularly see patients
with Alzheimer’s and related
dementias know that huge gaps
exist in our knowledge and our
ability to provide optimal care.
Neurologists, geriatricians, and
psychiatrists may be perceived as
the physicians who most often care
for Alzheimer’s patients, but there
is no doubt that it is generalist PCPs
who are providing the bulk of the
care of Alzheimer’s patients. In a
survey of PCPs in West Virginia
conducted by the Outreach Program
of the Blanchette Rockefeller
Neurosciences Institute (BRNI) in
mid-2009, 99% of respondents said
that they see at least one patient per
month with Alzheimer’s disease or a
related dementia, and a full 31% said

that they see 16 or more monthly.
Demographics alone make it likely
that virtually every PCP in the state
will see more than four Alzheimer’s
patients monthly, as there are
perhaps 46,000 victims in WV, and
approximately 1600 practicing PCPs
available to take care of them. This
review is intended to provide PCPs
with a practical, evidence-based
framework for approaching the many
affected patients who will come to
their offices – a way to stand in the
clinical gap while scientists work
furiously searching for the cure.

Recognition and Screening
Because dementia is by definition
an indolent disorder, recognition
of it is a challenge in primary care
offices, where the focus is often, of
necessity, one of rapid assessment
and speedy decision-making. The
fact that patients may have been
seeing the same physician for years
is potentially both a help and a
hindrance in discernment of the
subtle findings which signal the
onset of a dementing illness. These
changes might be more readily
apparent in familiar patients, in
whom PCPs may find the new
presence of a memory disturbance
to be relatively obvious; however,
when a primary care physician has
become accustomed to looking at
a particular set of problems in a
particular patient, one might not even

notice the onset of the typically very
nuanced early signs of dementia. So,
it is worthwhile for PCPs to consider
a defined set of warning signs or
clinical hints that a patient may be
in the early stages of dementia.
The Alzheimer’s Association
has recently published an updated
version of their “10 Warning Signs”,
a useful document for PCPs to
review and consider posting in their
offices. (This can be downloaded
from www.alz.org .) Widespread
public dissemination of this list
will help families and patients
themselves to decide when they
should inform their physician of
concerns about memory. A few other
clinical warning signs may not be as
immediately recognized as heralding
dementia, but should also be heeded
by physicians. These include:
• The Poor Historian: This timehonored description of the
patient who just can’t seem
to tell a coherent story about
their medical history may serve
as be a red flag; if a PCP is
tempted to note this as a feature
of a patient’s presentation, a
follow-up question should
always be asked - “Could this
be due to early dementia?”
• The Repetitive Caller: If the
front desk staff notices that a
patient has called several times
to check on some aspect of an
appointment, or if the nurse
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There is a huge volume of information recently published about Alzheimer’s disease, but most of it is not targeted to the average
busy primary care physician, even though these PCPs are providing the bulk of care to patients with dementia. This paper is a
succinct clinical review of the current state of diagnosis and treatment of Alzheimer’s disease, including citations of resources for
physicians and caregivers.
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reports that the patient called
multiple times for a refill, the
physician should “file” this
information, perhaps even
literally put a note in the chart
so it can be considered at the
patient’s next appointment.
• The Unexpectedly Delirious
Patient: Delirium, especially
occurring with a relatively
minor physiologic insult, may
presage the onset of dementia.
• The Patient with a New Best
Friend: Persons with dementia
are easy targets for those who
would exploit them, for monetary
or other purposes. When a
patient inexplicably appears at
the office with someone who
claims to have befriended them
or to have begun “helping”
them, for no obvious reason,
the clinician would be wise to
maintain a level of skepticism.
Once a problem is recognized, the
PCP should screen the patient with a
standardized instrument to ascertain
if the problem is a true memory
disorder. “Screening”, in terms of
community events or widespread
screening of asymptomatic
individuals, is not recommended.1
Home screening is particularly
discouraged. However, office-based
case finding is a necessity, and can
be accomplished with relatively
little time commitment and without
disruption of office routines. A
multitude of screening instruments
have been developed and are
available, but the clinical utility
of many of them is limited by the
amount of time or expertise required
to do the testing accurately. The WV
Alzheimer’s Outreach and Registry
Program (AORP) recommends that
PCPs use the “Mini-Cog” screening
tool. Briefly this consists of a three
word recall test and a clock drawing
exercise, which can be performed by
any trained person in the office (MA,
nurse, or physician), and has been

Table 1. The “Mini-Cog” Screening Instrument
The test:
• Give the patient a list of three simple words. (Example: “ball, flag, tree”
- or - “apple, penny, table”) Ask the patient to repeat the words so you
will know they have been heard and understood. Perform a Clock
Drawing Test. Ask the patient to: draw a circle; put in the numbers
as on the face of a clock; put in the hands of the clock to show a
particular time. (Choose a time in which the hands of the clock are
fairly separated, but not an “easy” time such as 3:00 or 6:00.) Ask the
patient to recall the three words.
The scoring:
• One point for each word recalled (without prompting)
• One point for normal clock, zero points for abnormal clock. (It is your
judgment call as to whether a clock is normal.)
o Three or four points – not supportive of dementia diagnosis
o Zero to two points – supportive of dementia diagnosis

demonstrated to require only about
three minutes to complete.2 (Table 1)

Diagnosis
If a screening test indicates a
possible dementia, the next step is
to attempt to firm up a diagnosis.
There is significant overlap in the
clinical presentation of Alzheimer’s
disease, vascular dementia, and
certain other common dementias,
and often a patient may have a
mixed disorder. PCPs realize, and
must make it clear to the patients
and families, that no clinically useful
test currently exists which will
unequivocally confirm a diagnosis
of Alzheimer’s disease. Certain tests
are necessary, though, to rule out
other causes of dementia, some of
which may be partially treatable.
While the history and physical
examination are critical, findings
may be non-specific; particularly
important features are noted in
Table 2. Likewise, laboratory
testing need not be extensive,
but certain critical tests must
be obtained. (Table 3).
Imaging is recommended by the
American Academy of Neurology.3
Depending on what is most readily
available in the area, and what other

clinical issues may be present in
the patient, CT or MRI of the head
may be ordered. Either will rule out
certain other unsuspected pathology,
and can help define the extent of
vascular changes. PET scanning,
with either FDG (glucose utilization
functional scanning) or with
“Pittsburgh Compound”/ PIB (which

Table 2. Physical Examination
Features of Alzheimer’s Disease
PE may be, and often is,
completely normal. Potentially
abnormal findings include:
• Anosmia
• “Bewildered” affect, especially
in later stages
• Failure of “One-Leg Standing”
test [cannot stand 5 seconds
on one leg]
• Numerous “subtle neurologic
abnormalities” [the presence
of subtle findings which
are non-diagnostic in and
of themselves, including:
generally diminished DTRs,
decreased grip strength,
pronator drift, etc.]
• Various speech abnormalities
involving content or fluency
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Table 3. Testing Needed in the Evaluation of Possible Alzheimer’s Disease
There is no clinically useful diagnostic test for Alzheimer’s at this time, but
several tests should be done to rule out other memory-loss disorders:
• Complete Blood Count; Complete Chemistry Profile
• Thyroid Function Tests
• B12 levels
• Neuroimaging – CT Scan or MRI of head
• Depression Screening

binds to amyloid), yields imaging
which best discriminates among
Alzheimer’s and other dementias,
and is the imaging modality which
comes closest to being a “diagnostic”
test. However, many insurance
carriers consider it to still be
“experimental”, and therefore they
will not cover it. Medicare covers PET
scanning for dementia diagnosis only
within the strict boundary of testing
to differentiate between Alzheimer’s
and Fronto-Temporal Dementia,
and only after documentation of

decline in mental status scores
over six months or more.
Other evaluation/diagnosis
strategies are under development,
including a skin biopsy technique
now being studied at BRNI. The
NIH is involved in a wide-ranging
study of neuroimaging, which
likewise is very promising but as
yet is not complete enough to yield
definitive recommendations.

Treatment
Once the PCP is comfortable
with a diagnosis of Alzheimer’s,

treatment must be considered, and
generally, three aspects should be
addressed – risk factor modification,
treatment of the disease, and
treatment of behaviors. (Table 4)

Addressing Risk Factors
Prevention of Alzheimer’s
cannot be guaranteed at this time,
because we simply don’t know
enough about the pathophysiology.
The best defined risks are roughly
the same as the known risk
factors of atherosclerotic disease,
including hypertension and
hypercholesterolemia. Recently
it has been more clearly shown
that diabetes mellitus4 and heavy
smoking5 in mid-life are independent
AD risk factors. Attempting to
modify Alzheimer’s risk factors
once the disease is manifest, in
an attempt to change the course
of the Alzheimer’s itself, may be
considered futile, and at this time in
history, it probably is. However, for

The sensible choice

for specialized care.

Providing comprehensive pediatric and adult eye care,
Eye & Ear Clinic Physicians also offers eyeglasses
and contact lens prescriptions, featuring a wide
selection of affordable frames and lenses.

304.343.EECP(3327) | eecpwv.com
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Table 4. Treatment Approaches for Alzheimer’s Disease
Disease-specific rx:
Cholinesterase Inhibitors (CHEI)
Donepezil (Aricept™)

Once daily dosing; long clinical experience

Rivastigmine (Exelon™)

Available in transdermal patch

Galantamine (Razadyne™)

Multiple dosing options

NMDA receptor blocker
Memantine (Namenda™)

Add-on to CHEI in late stages

Treatment of adverse behaviors:
		
Always attempt non-pharmacologic approaches first.
		Various medication classes may have a role in specific cases, including antidepressants, anti-anxiety
agents, antipsychotics. Must be tailored to patient and closely observed.
Risk factor modification:
		Treatment indicated for primary risk factors including hyperlipidemia, diabetes, hypertension, but “tight”
control, especially of diabetes, should be avoided once the dementia is clinically manifest.
		

Head protection, via fall avoidance and seat belt use, should be emphasized.

patients in early stages of the disease,
modest attempts to control risk
factors are reasonable. Good control
of hypertension is worthwhile,
and attaining some control of
hyperlipidemia and diabetes may be
useful. “Tight” control of diabetes
is not indicated due to the risk of
hypoglycemia, which itself is a
significant contributor to dementia.
Protection of the head by use of
seat belts and assistive devices for
ambulation should be continued,
for as long as the patient can
cooperate. Sepsis confers a three-fold
increase in the risk of subsequent
cognitive impairment, and so
should be aggressively treated.6
Disease Treatment
Treatment of Alzheimer’s
Disease itself can be attempted
with two categories of drugs. The
cholinesterase inhibitors have
been available for several years
and remain the first line choice for
treatment. These include donezepil,

galantamine and rivastigmine. The
second available medication is the
NMDA receptor blocker menantine,
which is recommended as an add-on
to treatment with a cholinesterase
inhibitor. Outcome of treatment
with these agents is variable, with an
occasional patient showing visible
improvement, but for the most part
they are given in hopes of slowing
disease progression. While there is
still a great deal of controversy as to
the true benefit of these medications,
they are currently all we have to
offer, and most patients and families
will want a trial of treatment.
Treatment of Behaviors
Non-pharmacologic approaches
to controlling adverse behaviors
must always be attempted before
drugs are used. Often, improving
caregivers’ understanding of
why patients behave the way
they do may forestall the need
for medication. The Alzheimer’s
Association is an excellent resource

for those seeking information about
these non-drug approaches.
Occasionally, however, all
attempts at non-drug therapy will
fail, and consideration will have
to be given to using psychotropic
medications. PCPs who find
themselves needing to prescribe
such medications in demented
patients should first be sure that
they are treating the patient and
not the caregiver. If a behavior,
hallucination/delusion, or sleep
disturbance is not a problem for the
patient, it requires no treatment. If
the patient is endangered, though,
by their own behavior, then
treatment will be necessary, and the
PCP will have to determine which
therapeutic class to use based on their
in‑depth knowledge of the patient.
Occasionally benzodiazepines,
antidepressants, or mood stabilizers
will have a place in treatment;
occasionally there are no options
left except antipsychotics. Of course
there are black-box warnings
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on these medications now, if
they are to be used in dementia,
and many physicians feel that
informed consent is necessary.
A recent meta-analysis supports
the use of cognitive interventions
for both behaviors and cognitive/
intellectual decline.7 The
interventions which have worked,
however, are specific therapies
administered by professionals, such
as “spaced retrieval techniques” and
“sensorimotor skill stimulation”,
not the simpler games and puzzles
often recommended or marketed for
this purpose. PCPs should inform
patients and families to remain
engaged with various activities,
but should discourage purchase
of special software or games.

Caregivers
Most of the care of Alzheimer’s
patients is provided by unpaid family
caregivers, and very often the care
must be given full time, with little
respite for the caregiver. The adverse
outcomes of caregiver stress are well
known, and their needs must not
be overlooked. The WV Bureau of
Senior Services has two programs
that may be beneficial for those who
qualify, “Lighthouse” and “FAIR”,

but the programs are underfunded,
and cannot provide services to
nearly all who need them. Again
the Alzheimer’s Association, and
also the WV chapter of the National
Family Caregivers Association
(www.thefamilycaregiver.org)
may be useful resources.

The Future
Much scientific work is underway
as we seek a cure for this devastating
disorder. West Virginia is privileged
to be home to the Blanchette
Rockefeller Neurosciences Institute,
the only privately endowed facility
in the nation devoted to researching
this disease, where currently
numerous studies are underway
regarding pathology, diagnosis, and
treatment. An Alzheimer’s Registry
is also under development at BRNI.
PCPs will use this more than any
other group of practitioners and
BRNI will be providing extensive
education prior to the registry
being fully implemented.
Additionally, though, our
societal commitment as a nation
must improve, because currently,
for each cent that the NIH devotes
to Alzheimer’s research, we spend

$3.50 on the care of persons with
the disease.8 As the nation ages,
the prevalence of Alzheimer’s
will continue to increase; we
simply must have more research
on both prevention and cure.
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CME Post-Test
4.

Which statement is true regarding screening for dementia?
a. Large community-based screenings at health fairs are very useful and easy to do.
b. Case-finding, with standardized assessment tools, can be done in a primary care office without disruption of
patient flow.
c. Screening is not necessary, as the diagnosis is always obvious soon after onset of the disorder.
d. The most efficient screening tool is the ADAS-Cog.

5.	Two categories of drugs are currently on the market for treatment of Alzheimer’s Disease. Of the two, the one
recommended for an initial treatment trial is:
a. ACE Inhibitor
b. NMDA receptor blocker
c. Cholinesterase inhibitor
d. Antioxidant
6.	Special software, games, and activities are currently being marketed as tools for both cognitively normal persons and
early dementia patients to use to maintain or improve memory and cognitive flexibility. These items are:
a. Strongly recommended as proven and reliable
b. Too simple for even the average Alzheimer’s patient
c. Equal in effectiveness to cognitive interventions performed by professional therapists
d. Not as effective as specific therapies such as sensorimotor skill stimulation.
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